J. Goldman & Co’s iShares Biotechnology ETF IBB Stock Holding History

J. Goldman & Co’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.64M	Buy	+34,900	New	+$6M	0.17%	163
2026 Q1	–	Sell	-40,000	Closed	-$6.75M	–	762
2025 Q4	$6.75M	Buy	40,000 +20,000	+100%	+$3.25M	0.18%	158
2025 Q3	$2.89M	Buy	20,000 +14,000	+233%	+$1.91M	0.07%	248
2025 Q2	$759K	Sell	6,000 -23,400	-80%	-$2.87M	0.02%	354
2025 Q1	$3.76M	Buy	29,400 +6,700	+30%	+$908K	0.09%	235
2024 Q4	$3M	Buy	+22,700	New	+$3.19M	0.08%	239
2024 Q2	–	Sell	-20,000	Closed	-$2.74M	–	515
2024 Q1	$2.74M	Sell	20,000 -95,200	-83%	-$13M	0.09%	195
2023 Q4	$15.6M	Buy	+115,200	New	+$14.1M	0.63%	52
2023 Q2	–	Sell	-35,000	Closed	-$4.52M	–	433
2023 Q1	$4.52M	Buy	+35,000	New	+$4.58M	0.18%	150
2019 Q3	–	Sell	-40,000	Closed	-$4.36M	–	317
2019 Q2	$4.36M	Buy	+40,000	New	+$4.25M	0.3%	107
2015 Q3	–	Sell	-48,000	Closed	-$5.9M	–	266
2015 Q2	$5.9M	Buy	+48,000	New	+$5.75M	0.36%	76

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

J. Goldman & Co's IBB Position: Q2 2026 in Review

J. Goldman & Co sold out of iShares Biotechnology ETF (IBB) in Q2 2026, closing a stake of 2,301 shares — an estimated $395K sold.

J. Goldman & Co first reported a position in IBB in Q1 2016 and held it in 9 quarters. The position peaked at $1.37M in Q2 2024. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

J. Goldman & Co reported no remaining iShares Biotechnology ETF position as of Q2 2026 after selling out during the quarter.
J. Goldman & Co sold 2,301 iShares Biotechnology ETF shares in Q2 2026, an estimated $395K.
J. Goldman & Co first reported a position in iShares Biotechnology ETF in Q1 2016 and held it in 9 quarters.
J. Goldman & Co's iShares Biotechnology ETF position peaked at $1.37M in Q2 2024.
956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.